Bli medlem
Bli medlem

Du är här


Moberg Pharma: Redeye: Moberg Pharma - Major inflection points approaching

The recently announced agreements in Asia brings further external
validation of MOB-015 as a promising new topical treatment of
onychomycosis, boosting our conviction about the case ahead of the
first top-line results expected in December. The share price has
performed strongly in 2019 (+78%), but we see further upside for the
stock before the top-line results.

Read more and download the Research Update:

Start following companies at Redeye to receive the latest equity
research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment


Författare Cision News

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.